A Review of the Preclinical and Clinical Efficacy of Remdesivir, Hydroxychloroquine, and Lopinavir-Ritonavir Treatments against COVID-19

In December of 2019, an outbreak of a novel coronavirus flared in Wuhan, the capital city of the Hubei Province, China. The pathogen has been identified as a novel enveloped RNA beta-coronavirus named severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). The virus SARS-CoV-2 is associated with a disease characterized by severe atypical pneumonia known as coronavirus 2019 (COVID-19). Typical symptoms of this disease include cough, fever, malaise, shortness of breath, gastrointestinal symptoms, anosmia, and, in severe cases, pneumonia.1 The high-risk group of COVID-19 patients includes people over the age of 60 years as well as people with existing cardiovascular disease and/or diabetes mellitus. Epidemiological investigations have suggested that the outbreak was associated with a live animal market in Wuhan. Within the first few months of the outbreak, cases were growing exponentially all over the world. The unabated spread of this deadly and highly infectious virus is a health emergency for all nations in the world and has led to the World Health Organization (WHO) declaring a pandemic on March 11, 2020. In this report, we consolidate and review the available clinically and preclinically relevant results emanating from in vitro animal models and clinical studies of drugs approved for emergency use as a treatment for COVID-19, including remdesivir, hydroxychloroquine, and lopinavir-ritonavir combinations. These compounds have been frequently touted as top candidates to treat COVID-19, but recent clinical reports suggest mixed outcomes on their efficacies within the current clinical protocol frameworks.

Download Full-text

Treatment Options in COVID-19: The Role of Bioavailable Antiviral Ribonucleoside Analog on NHC in vitro

Journal of Regenerative Biology and Medicine ◽

10.37191/mapsci-2582-385x-2(1)-024 ◽

2020 ◽

Author(s):

Lara Bittmann

Keyword(s):

World Health Organization ◽

Clinical Picture ◽

Treatment Options ◽

World Health ◽

Wuhan City ◽

The World ◽

Novel Coronavirus ◽

Health Organization

On December 31, 2019, WHO was informed of cases of pneumonia of unknown cause in Wuhan City, China. A novel coronavirus was identified as the cause by Chinese authorities on January 7, 2020 and was provisionally named "2019-nCoV". This new Coronavirus causes a clinical picture which has received now the name COVID-19. The virus has spread subsequently worldwide and was explained on the 11th of March, 2020 by the World Health Organization to the pandemic.

Download Full-text

A comparison of COVID-19, SARS and MERS

PeerJ ◽

10.7717/peerj.9725 ◽

2020 ◽

Vol 8 ◽

pp. e9725 ◽

Cited By ~ 3

Author(s):

Tingting Hu ◽

Ying Liu ◽

Mingyi Zhao ◽

Quan Zhuang ◽

Linyong Xu ◽

...

Keyword(s):

Severe Acute Respiratory Syndrome ◽

Case Fatality ◽

Hubei Province ◽

World Health ◽

Atypical Pneumonia ◽

Organization Studies ◽

Optimal Method ◽

The World ◽

Novel Coronavirus ◽

Health Organization

In mid-December 2019, a novel atypical pneumonia broke out in Wuhan, Hubei Province, China and was caused by a newly identified coronavirus, initially termed 2019 Novel Coronavirus and subsequently severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). As of 19 May 2020, a total of 4,731,458 individuals were reported as infected with SARS-CoV-2 among 213 countries, areas or territories with recorded cases, and the overall case-fatality rate was 6.6% (316,169 deaths among 4,731,458 recorded cases), according to the World Health Organization. Studies have shown that SARS-CoV-2 is notably similar to (severe acute respiratory syndrome coronavirus) SARS-CoV that emerged in 2002–2003 and Middle East respiratory syndrome coronavirus (MERS-CoV) that spread during 2012, and these viruses all contributed to global pandemics. The ability of SARS-CoV-2 to rapidly spread a pneumonia-like disease from Hubei Province, China, throughout the world has provoked widespread concern. The main symptoms of coronavirus disease 2019 (COVID-19) include fever, cough, myalgia, fatigue and lower respiratory signs. At present, nucleic acid tests are widely recommended as the optimal method for detecting SARS-CoV-2. However, obstacles remain, including the global shortage of testing kits and the presentation of false negatives. Experts suggest that almost everyone in China is susceptible to SARS-CoV-2 infection, and to date, there are no effective treatments. In light of the references published, this review demonstrates the biological features, spread, diagnosis and treatment of SARS-CoV-2 as a whole and aims to analyse the similarities and differences among SARS-CoV-2, SARS-CoV and MERS-CoV to provide new ideas and suggestions for prevention, diagnosis and clinical treatment.

Download Full-text

The outbreak of Novel Coronavirus a New Type of Threat in 2020: Genesis, Detection, Treatment, and Management

Coronaviruses ◽

10.2174/2666796701999200905093719 ◽

2020 ◽

Vol 01 ◽

Author(s):

Dinesh Mohan S ◽

Santhosha D ◽

Gupta VRM ◽

Mrunalini S

Keyword(s):

Respiratory Tract ◽

Lower Respiratory Tract ◽

Primary Source ◽

World Health ◽

London School ◽

Live Animal ◽

The World ◽

Novel Coronavirus ◽

Health Organization ◽

Approved Drugs

Background: COVID-19 is a new, health-threatening infectious disease in the world in 2020, caused novel coronavirus SARS-CoV-2. As of July 13, 2020, 4,881,579 active cases of COVID-19 have been diagnosed and 571,080 deaths globally. In India, 301,850 active cases and 23,187 deaths have been reported. To date, there is no effective treatment made available against the deadly virus SARS-CoV-2. The drug manufacturers, institutional laboratories, and other organizations start developing vaccines to combat the COVID-19 infection. Methods: Science Direct, Elsevier, Pub med, Scopus, and Nature databases were referred to know the current scenario of disease. Moreover, the recent data has also been obtained from the World Health Organization (WHO), Centre of Disease Control (CDCs), case studies, newspaper, and worldometer reports. Vaccine Centre at the London School of Hygiene & Tropical Medicine, Clinicaltrials.gov, US National Library of Medicine, has also been accessed to get the latest information about ongoing clinical trials. Result: The primary source of the SARS-CoV-2 outbreak is connected to the Hunan seafood and live animal market in Wuhan city, Hubei Province, China. Like; SARS-CoV, and MERS-CoV, SARS-CoV-2 is also a zoonotic virus affecting the lower respiratory tract in humans. The pathogenesis of COVID-19 involves attachment of its Spike (S) protein to the angiotensin-converting enzyme 2 (ACE2) receptor in the lower respiratory tract in humans. The most common symptoms of COVID-19 are fever, cough, sore throat, fatigue, headache, myalgia, septic shock, and breathlessness. Few patients with COVID-19 infection experience diarrhea, vomiting, and abdominal pain. Currently, FDA approved drugs being used to treat COVID-19. Conclusion: This review article presents the importance of traditional Indian herbs recommended by AYUSH as precautionary and curative measures of COVID-19 until vaccines and drugs are made available. Moreover, this article discussed the origin, symptoms, mode of transmission, management, and diagnostics techniques for the detection of the SARS-CoV-2 virus.

Download Full-text

Current updates on COVID-19 - A review

International Journal of Novel Trends in Pharmaceutical Sciences ◽

10.26452/ijntps.v10i1.1141 ◽

2020 ◽

Vol 10 (1) ◽

pp. 1-8

Author(s):

Ghotekar D S ◽

Vishal N Kushare ◽

Sagar V Ghotekar

Keyword(s):

World Health Organization ◽

Common Cold ◽

Respiratory Diseases ◽

Gastrointestinal Diseases ◽

Hubei Province ◽

World Health ◽

The World ◽

The Common ◽

Novel Coronavirus ◽

Health Organization

Coronaviruses are a family of viruses that cause illness such as respiratory diseases or gastrointestinal diseases. Respiratory diseases can range from the common cold to more severe diseases. A novel coronavirus outbreak was first documented in Wuhan, Hubei Province, China in December 2019. The World Health Organization (WHO) has declared the coronavirus disease 2019 (COVID-19) a pandemic. A global coordinated effort is needed to stop the further spread of the virus. A novel coronavirus (nCoV) is a new strain that has not been identified in humans previously. Once scientists determine exactly what coronavirus it is, they give it a name (as in the case of COVID-19, the virus causing it is SARS-CoV-2).

Download Full-text

Natural products from the traditional Moroccan pharmacopoeia: A potential lead for the prevention and treatment of COVID-19

International Journal of Research in Pharmaceutical Sciences ◽

10.26452/ijrps.v11ispl1.3619 ◽

2020 ◽

Vol 11 (SPL1) ◽

pp. 1278-1285

Author(s):

Mohamed Yafout ◽

Amine Ousaid ◽

Ibrahim Sbai El Otmani ◽

Youssef Khayati ◽

Amal Ait Haj Said

Keyword(s):

Medicinal Plants ◽

Plant Extracts ◽

Molecular Mechanisms ◽

Scientific Literature ◽

Treatment Protocol ◽

World Health ◽

The World ◽

Health Organization ◽

Promising Source

The new SARS-CoV-2 belonging to the coronaviruses family has caused a pandemic affecting millions of people around the world. This pandemic has been declared by the World Health Organization as an international public health emergency. Although several clinical trials involving a large number of drugs are currently underway, no treatment protocol for COVID-19 has been officially approved so far. Here we demonstrate through a search in the scientific literature that the traditional Moroccan pharmacopoeia, which includes more than 500 medicinal plants, is a fascinating and promising source for the research of natural molecules active against SARS-CoV-2. Multiple in-silico and in-vitro studies showed that some of the medicinal plants used by Moroccans for centuries possess inhibitory activity against SARS-CoV or SARS-CoV-2. These inhibitory activities are achieved through the different molecular mechanisms of virus penetration and replication, or indirectly through stimulation of immunity. Thus, the potential of plants, plant extracts and molecules derived from plants that are traditionally used in Morocco and have activity against SARS-CoV-2, could be explored in the search for a preventive or curative treatment against COVID-19. Furthermore, safe plants or plant extracts that are proven to stimulate immunity could be officially recommended by governments as nutritional supplements.

Download Full-text

An approach to the understanding of the clinical-etiopathological aspect of COVID-19 (SARS-CoV-2)

International Journal of Research in Pharmaceutical Sciences ◽

10.26452/ijrps.v11ispl1.3094 ◽

2020 ◽

Vol 11 (SPL1) ◽

pp. 862-869

Author(s):

Meena Kumari ◽

Monika Agrawal ◽

Rakesh Kumar Singh ◽

Parameswarappa S Byadgi

Keyword(s):

World Health ◽

Apical Surface ◽

Therapy Assessment ◽

Differentiated Cells ◽

The World ◽

Polarized Epithelia ◽

Well Differentiated ◽

Novel Coronavirus ◽

Health Organization ◽

Epidemiological Characteristics

Currently, the world is facing a health and socioeconomic crisis caused by the novel coronavirus disease COVID-19. On 11 March 2020, the World Health Organization (WHO) has declared this disease as a pandemic. The condition (COVID-19) is an infectious disorder triggered by a newly discovered severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2. Most of the COVID-19 infected patients will experience mild to moderate respiratory symptoms and recover without any unique therapy. Assessment of the clinical and epidemiological characteristics of SARS-CoV-2 cases suggests the infected patients will not be contagious until the onset of severe symptoms and affects the other organs. Well-differentiated cells of apical airway epithelia communicating with ACE2 were promptly infected to SARS-CoV-2 virus. But the expression of ACE 2 in poorly differentiated epithelia facilitated SARS spike (S) protein-pseudo typed virus entry and it is replicated in polarized epithelia and especially exited via the apical surface. Limiting the transmission of COVID-19 infection & its prevention can be regarded as a hierarchy of controls. In this article, we briefly discuss the most recent advances in respect to aetiology, pathogenesis and clinical progression of the disease COVID-19.

Download Full-text

Critical Insight into the Attributes of Emerging Novel Coronavirus (COVID-19) in India and Across the World

Coronaviruses ◽

10.2174/2666796701999200623172631 ◽

2020 ◽

Vol 1 (1) ◽

pp. 49-56

Author(s):

Gaurav M. Doshi ◽

Hemen S. Ved ◽

Ami P. Thakkar

Keyword(s):

Review Article ◽

World Health ◽

Effective Vaccine ◽

Human Contact ◽

The World ◽

Critical Insight ◽

Novel Coronavirus ◽

Health Organization ◽

Insight Into ◽

Old Drugs

The World Health Organization (WHO) has recently announced the spread of novel coronavirus (nCoV) globally and has declared it a pandemic. The probable source of transmission of the virus, which is from animal to human and human to human contact, has been established. As per the statistics reported by the WHO on 11th April 2020, data has shown that more than sixteen lakh confirmed cases have been identified globally. The reported cases related to nCoV in India have been rising substantially. The review article discusses the characteristics of nCoV in detail with the probability of potentially effective old drugs that may inhibit the virus. The research may further emphasize and draw the attention of the world towards the development of an effective vaccine as well as alternative therapies. Moreover, the article will help to bridge the gap between the new researchers since it’s the current thrust area of research.

Download Full-text

The Pandemic of Novel Coronavirus Disease 2019 (COVID-19): Need for an Immediate Action (Preprint)

10.2196/preprints.19628 ◽

2020 ◽

Author(s):

Mujib Ullah

Keyword(s):

World Health Organization ◽

Large Family ◽

Current Treatment ◽

World Health ◽

New Disease ◽

The World ◽

Novel Coronavirus ◽

Health Organization

UNSTRUCTURED Coronaviruses belong to a large family of viruses. Coronavirus also called COVID-19 is a new disease that has not been previously identified in humans. The World Health Organization has announced that COVID-19 is a pandemic. Currently there is no specific vaccine or treatment for COVID-19. Current treatment for COVID-19 is only supportive (treating the symptoms). There are no antiviral or vaccine options at this time. Therefore, it is time to bring collective efforts to treat or prevent a rapidly evolving pandemic of COVID-19.

Download Full-text

Progression and Trends in Virus from Influenza A to COVID-19: An Overview of Recent Studies

Viruses ◽

10.3390/v13061145 ◽

2021 ◽

Vol 13 (6) ◽

pp. 1145

Author(s):

Hakimeh Baghaei Daemi ◽

Muhammad Fakhar-e-Alam Kulyar ◽

Xinlin He ◽

Chengfei Li ◽

Morteza Karimpour ◽

...

Keyword(s):

Influenza A ◽

H1n1 Virus ◽

World Health ◽

H1n1 Pandemic ◽

Global Pandemic ◽

First Case ◽

Influenza A H1n1 ◽

The World ◽

Novel Coronavirus ◽

Health Organization

Influenza is a highly known contagious viral infection that has been responsible for the death of many people in history with pandemics. These pandemics have been occurring every 10 to 30 years in the last century. The most recent global pandemic prior to COVID-19 was the 2009 influenza A (H1N1) pandemic. A decade ago, the H1N1 virus caused 12,500 deaths in just 19 months globally. Now, again, the world has been challenged with another pandemic. Since December 2019, the first case of a novel coronavirus (COVID-19) infection was detected in Wuhan. This infection has risen rapidly throughout the world; even the World Health Organization (WHO) announced COVID-19 as a worldwide emergency to ensure human health and public safety. This review article aims to discuss important issues relating to COVID-19, including clinical, epidemiological, and pathological features of COVID-19 and recent progress in diagnosis and treatment approaches for the COVID-19 infection. We also highlight key similarities and differences between COVID-19 and influenza A to ensure the theoretical and practical details of COVID-19.

Download Full-text